99 related articles for article (PubMed ID: 28718403)
1. Genomic and proteomic biomarkers for cancer: a multitude of opportunities.
Tainsky MA
Biochim Biophys Acta; 2009 Dec; 1796(2):176-93. PubMed ID: 19406210
[TBL] [Abstract][Full Text] [Related]
2. Synthetic biomarkers: a twenty-first century path to early cancer detection.
Kwong GA; Ghosh S; Gamboa L; Patriotis C; Srivastava S; Bhatia SN
Nat Rev Cancer; 2021 Oct; 21(10):655-668. PubMed ID: 34489588
[TBL] [Abstract][Full Text] [Related]
3. Innovations, challenges and future prospects of oncoproteomics.
Jain KK
Mol Oncol; 2008 Aug; 2(2):153-60. PubMed ID: 19383334
[TBL] [Abstract][Full Text] [Related]
4. The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers.
Srivastava S; Wagner PD
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2401-2410. PubMed ID: 32357955
[TBL] [Abstract][Full Text] [Related]
5. Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy.
Hewitt SM; Badve SS; True LD
Clin Cancer Res; 2012 Mar; 18(6):1524-30. PubMed ID: 22422404
[TBL] [Abstract][Full Text] [Related]
6. Proteomics and Its Applications in Cancers 2.0.
Naryzhny S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674032
[TBL] [Abstract][Full Text] [Related]
7. ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance.
Conrad C; Benzel J; Dorzweiler K; Cook L; Schlomann U; Zarbock A; Slater EP; Nimsky C; Bartsch JW
Clin Sci (Lond); 2019 Jan; 133(1):83-99. PubMed ID: 30635388
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory role of metalloproteases in cancers: Current progress and future trends.
Wang Q; Wang K; Tan X; Li Z; Wang H
Front Immunol; 2022; 13():1064033. PubMed ID: 36591235
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway.
Zhu W; Shi L; Gong Y; Zhuo L; Wang S; Chen S; Zhang B; Ke B
Thorac Cancer; 2022 Apr; 13(7):1027-1039. PubMed ID: 35178875
[TBL] [Abstract][Full Text] [Related]
10. Extracellular Matrix Biomarkers in Colorectal Cancer.
Kim MS; Ha SE; Wu M; Zogg H; Ronkon CF; Lee MY; Ro S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502094
[TBL] [Abstract][Full Text] [Related]
11. Exploring the landscape of ectodomain shedding by quantitative protein terminomics.
Tsumagari K; Chang CH; Ishihama Y
iScience; 2021 Apr; 24(4):102259. PubMed ID: 33796845
[TBL] [Abstract][Full Text] [Related]
12. Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study.
Pichler R; Lindner AK; Schäfer G; Tulchiner G; Staudacher N; Mayr M; Comperat E; Orme JJ; Schachtner G; Thurnher M
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33672843
[TBL] [Abstract][Full Text] [Related]
13. The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma.
Qi B; Liu H; Dong Y; Shi X; Zhou Q; Zeng F; Bao N; Li Q; Yuan Y; Yao L; Xia S
PeerJ; 2020; 8():e9736. PubMed ID: 33062410
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
Guo Y; He X; Zhang M; Qu Y; Gu C; Ren M; Wang H; Ning W; Li J; Yu C; Zhang H
J Neurooncol; 2020 Apr; 147(2):327-337. PubMed ID: 32170633
[TBL] [Abstract][Full Text] [Related]
15. Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.
Pirlog R; Susman S; Iuga CA; Florian SI
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31357616
[TBL] [Abstract][Full Text] [Related]
16. Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness.
Nwogu N; Boyne JR; Dobson SJ; Poterlowicz K; Blair GE; Macdonald A; Mankouri J; Whitehouse A
PLoS Pathog; 2018 Sep; 14(9):e1007276. PubMed ID: 30188954
[TBL] [Abstract][Full Text] [Related]
17. High Resolution Proteomic Analysis of the Cervical Cancer Cell Lines Secretome Documents Deregulation of Multiple Proteases.
Pappa KI; Kontostathi G; Makridakis M; Lygirou V; Zoidakis J; Daskalakis G; Anagnou NP
Cancer Genomics Proteomics; 2017; 14(6):507-521. PubMed ID: 29109100
[TBL] [Abstract][Full Text] [Related]
18. ADAM Metalloprotease-Released Cancer Biomarkers.
Herrlich P; Herrlich A
Trends Cancer; 2017 Jul; 3(7):482-490. PubMed ID: 28718403
[TBL] [Abstract][Full Text] [Related]
19. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
